Resveratrol, a polyphenol phytoalexin, protects against doxorubicin-induced cardiotoxicity

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 10, 2015, Pages 2324-2328

  Gu, Jun ^a,b   Hu, Wei ^b   Zhang, Da Dong ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

ROS; Apoptosis; Autophagy; Cardiotoxicity; Doxorubicin; Resveratrol

Indexed keywords

CASPASE 3; DOXORUBICIN; PROTEIN BAX; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA1; CARDIOTONIC AGENT; PHYTOALEXINS; SESQUITERPENE; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CARDIOTOXICITY; GENE EXPRESSION; HEART INJURY; HEART MUSCLE FIBROSIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CARDIAC MUSCLE CELL; DRUG EFFECTS; PATHOLOGY;

ANIMALS; CARDIOTONIC AGENTS; CARDIOTOXICITY; DOXORUBICIN; HUMANS; MYOCYTES, CARDIAC; SESQUITERPENES; STILBENES;

EID: 84942342527     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12633     Document Type: Article

References (35)

1. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014; 64: 938-45.
2. Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev. 2004; 22: 169-88.
3. Ray PS, Maulik G, Cordis GA, et al. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med. 1999; 27: 160-9.
4. Li H, Förstermann U. Resveratrol: a multifunctional compound improving endothelial function. Cardiovasc Drugs Ther. 2009; 23: 425-9.
5. Ramprasath VR, Jones PJ. Anti-atherogenic effects of resveratrol. Eur J Clin Nutr. 2010; 6: 660-8.
6. Dutta D, Xu J, Dirain ML, et al. Calorie restriction combined with resveratrol induces autophagy and protects 26-month-old rat hearts from doxorubicin-induced toxicity. Free Radic Biol Med. 2014; 74: 252-62.
7. Danz ED, Skramsted J, Henry N, et al. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med. 2009; 46: 1589-97.
8. Zhang C, Feng Y, Qu S, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res. 2011; 90: 538-45.
9. Tatlidede E, Sehirli O, Velioğlu-Oğünc A, et al. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res. 2009; 43: 195-205.
10. Xu X, Chen K, Kobayashi S, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther. 2012; 341: 183-95.
11. Sin TK, Tam BT, Yung BY, et al. Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis. J Physiol. 2015; 593: 1887-99.
12. Gu J, Song ZP, Gui DM, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc Toxicol. 2012; 12: 341-9.
13. Singal PK, Iliskovic N, Li T, et al. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997; 11: 931-6.
14. Arafa MH, Mohammad NS, Atteia HH, et al. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem. 2014; 70: 701-11.
15. Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem. 2012; 113: 752-9.
16. Ungvari Z, Bagi Z, Feher A, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol. 2010; 299: H18-24.
17. Han X, Ren D, Fan P, et al. Protective effects of naringenin-7-O-glucoside on doxorubicin-induced apoptosis in H9C2 cells. Eur J Pharmacol. 2008; 581: 47-53.
18. Moreira AC, Branco AF, Sampaio SF, et al. Mitochondrial apoptosis-inducing factor is involved in doxorubicin-induced toxicity on H9c2 cardiomyoblasts. Biochim Biophys Acta. 2014; 1842: 2468-78.
19. Usta E, Mustafi M, Walker T, et al. Resveratrol suppresses apoptosis in intact human cardiac tissue - in vitro model simulating extracorporeal circulation. J Cardiovasc Surg. 2011; 52: 399-409.
20. Dirks-Naylor AJ. The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci. 2013; 93: 913-6.
21. Lu L, Wu W, Yan J, et al. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int J Cardiol. 2009; 134: 82-90.
22. Kobayashi S, Volden P, Timm D, et al. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem. 2010; 285: 793-804.
23. Chen K, Xu X, Kobayashi S, et al. Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms. J Biol Chem. 2011; 286: 21993-2006.
24. Dimitrakis P, Romay-Ogando MI, Timolati F, et al. Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes. Cell Tissue Res. 2012; 350: 361-72.
25. Kawaguchi T, Takemura G, Kanamori H, et al. Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. Cardiovasc Res. 2012; 96: 456-65.
26. Sishi BJ, Loos B, van Rooyen J, et al. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem Pharmacol. 2013; 85: 124-34.
27. Wang X, Wang XL, Chen HL, et al. Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem Pharmacol. 2014; 88: 334-50.
28. Wang B, Yang Q, Sun YY, et al. Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. J Cell Mol Med. 2014; 18: 1599-611.
29. Kanamori H, Takemura G, Goto K, et al. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am J Pathol. 2013; 182: 701-13.
30. Lekli I, Ray D, Mukherjee S, et al. Co-ordinated autophagy with resveratrol and γ-tocotrienol confers synergetic cardioprotection. J Cell Mol Med. 2010; 14: 2506-18.
31. Alayev A, Doubleday PF, Berger SM, et al. Phosphoproteomics reveals resveratrol-dependent inhibition of Akt/mTORC1/S6K1 signaling. J Proteome Res. 2014; 13: 5734-42.
32. Chan V, Fenning A, Iyer A, et al. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol. 2011; 12: 429-36.
33. Sheu MT, Jhan HJ, Hsieh CM, et al. Efficacy of antioxidants as a complementary and alternative medicine (CAM) in combination with the chemotherapeutic agent doxorubicin. Integr Cancer Ther. 2015; 14: 184-95.
34. Kim TH, Shin YJ, Won AJ, et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta. 2014; 1840: 615-25.
35. Osman AM, Al-Harthi SE, AlArabi OM, et al. Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int. 2013; 13: 52.